Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, LLC, announced on July 20 that it entered into an agreement to acquire Genpro Research.
Genpro Research is a Massachusetts-based global clinical research organization (CRO) that serves the pharmaceutical, biotechnology and medical devices industries. It has staff in the United States, India and Ireland.
Catalyst is a clinical development organization providing customizable clinical research solutions to the global biopharmaceutical industry through two established solutions: Catalyst Flex and Catalyst Oncology. The company provides multi-therapeutic global resourcing and functional services through Catalyst Flex and a full-service oncology CRO offering through Catalyst Oncology. It operates across more than 35 countries and has more than 700 employees on staff.
This acquisition adds more than 120 team members in India with expertise in biometrics and medical writing further bolstering Catalyst’s robust functional service offerings. Terms were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 21st CRO acquisition of the year. This transaction, additionally, marks Catalyst’s first acquisition of the year. In 2022, the company purchased United Kingdom-based Aptus Clinical, a CRO offering clinical research solutions in oncology, cell and gene therapies and rare diseases.
